Inositol for subfertile women with polycystic ovary syndrome

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  Showell, Marian G ^a   Mackenzie Proctor, Rebecca ^b   Jordan, Vanessa ^a   Hodgson, Ruth ^b   Brown, Julie ^c   Farquhar, Cindy ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL; PLACEBO;

ARTICLE; CINAHL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; FEMALE; FEMALE SUBFERTILITY; HUMAN; MEDLINE; OVARY POLYCYSTIC DISEASE; PREGNANCY OUTCOME; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

EID: 84989259699     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012378     Document Type: Article

References (45)

1. Abu Hashim H. Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach. Archives of Gynecology and Obstetrics 2012; Vol. 285, issue 6:1737-45. [1432-0711]
2. Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertility and Sterility 2013;99(1):63.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility 2009;91(2):456-88.
4. Balen AH, Tan SL, Jacobs HS. Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage. British Journal of Obstetrics and Gynaecology 1993;100(12):1082-9.
5. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important?. Human Reproduction 2002;17(9):2219-27.
6. Beemster P, Groenen P, Steegers-Theunissen R. Involvement of inositol in reproduction. Nutrition Reviews 2002;60(3):80-7. [0029-6643]
7. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009, issue 4. [DOI: 10.1002/14651858.CD002249.pub4; CD002249]
8. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. The Journal of Clinical Endocrinology and Metabolism. UNITED STATES, 1980; Vol. 50, issue 1:113-6. [0021-972X]
9. Ching HL, Burke V, Stuckey BGA. Quality of life and psychological morbidity in women with polycystic ovary syndrome: Body mass index, age and the provision of patient information are significant modifiers. Clinical Endocrinology 2007; Vol. 66:373-9.
10. https://www.covidence.org/. COVIDENCE. https://www.covidence.org/, 2016.
11. Dias S, McNamee R, Vail A. Evidence of improving quality of reporting of randomized controlled trials in subfertility. Human Reproduction 2006;21(10):2617-27.
12. Facchinetti F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, et al. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2015; Vol. 195:72-6.
13. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility 2012; Vol. 97, issue 1:28-38 e25. [1556-5653: (Electronic)]
14. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010287.pub2]
15. Franks S. Polycystic ovary syndrome. The New England Journal of Medicine 1995;333(13):853-61.
16. Galazis N, Galazi M, Atiomo W. D-chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecological Endocrinology 2011;27(4):256-62.
17. Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecological Endocrinology 2014; Vol. 30, issue 6:438-43.
18. Genazzani AD, Santagni S, Ricchieri F, Campedelli A, Rattighieri E, Chierchia E, et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. Journal of Obstetrics & Gynaecology Research 2014; Vol. 40, issue 5:1353-60.
19. Glueck CJ, Dharashivkar S, Wang P, Zhu B, Gartside PS, Tracy T, et al. Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. European Journal of Obstetrics, Gynecology, and Reproductive Biology. Ireland: Elsevier Ireland Ltd, 2005; Vol. 122, issue 2:206-12.
20. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
22. Higgins JP, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
23. Iuorno MJ, Jakubowicz DJ, Baillargeon J-P, Dillon P, Gunn RD, Allan G, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrine Practice 2002; Vol. 8, issue 6:417-23.
24. Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecological Endocrinology 2015; Vol. 31, issue 2:131-5.
25. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook forSystematic Reviews of Interventions Version5.1.0 (updated March 2011). The CochraneCollaboration, 2011. Available from handbook.cochrane.org.
26. Lisi F. Pretreatment with Myo-inositol in patients undergoing gonadotropins multiple follicular stimulation for IVF. Acta Medica International. India: Teerthanker Mahaveer University (E-mail: apadu@yahoo.in), 2016; Vol. 3, issue 1:8-10.
27. Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reproductive Biomedicine Online 2008;17(4):579-82.
28. Minozzi M, Nordio M, Pajalich R. The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. European Review for Medical & Pharmacological Sciences 2013; Vol. 17, issue 4:537-40.
29. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility 2009;92(6):1966-82.
30. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2011, Issue 7.
31. Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecological Endocrinology 2015; Vol. 31, issue 7:501-5.
32. Papaleo E, Molgora M, Quaranta L, Pellegrino M, De Michele F. Myo-inositol products in polycystic ovary syndrome (PCOS) treatment: quality, labeling accuracy, and cost comparison. European Review for Medical & Pharmacological Sciences 2011; Vol. 15, issue 2:165-74.
33. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
34. Rosalbino R, Raffone E. Does ovary need D-chiro-inositol?. Journal of Ovarian Research 2012; Vol. 5, issue 1:14.
35. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004; Vol. 81, issue 1:19-25. [0015-0282: (Print)]
36. Ruder EH, Hartman TJ, Blumberg J, Goldman MB. Oxidative stress and antioxidants: exposure and impact on female fertility. Human Reproduction Update 2008;14(4):345-57.
37. Scottish Intercollegiate Guidelines Network (SIGN). http://www.sign.ac.uk/methodology/filters.html.
38. Seyedoshohadaei Fariba, Tangestani Laleh, Zandvakili Farnaz, Rashadmanesh Naser. Comparison of the Effect of Clomiphene- Estradiol Valerate vs Letrozole on Endometrial Thickness, Abortion and Pregnancy Rate in Infertile Women with Polycystic Ovarian Syndrome. Journal of clinical and diagnostic research : JCDR 2016;10(8):QC10-3.
39. Shaikh N, Dadachanji R, Meherji P, Shah N, Mukherjee S. Polymorphisms and haplotypes of insulin-like factor 3 gene are associated with risk of polycystic ovary syndrome in Indian women. Gene 2016;577(2):180-6. [PUBMED: 26625974]
40. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2012, Issue 5.
41. Tarlatzis BC, Fauser BC, Legro RS, Norman RJ, Hoeger K, Pasquali R, et al. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction. United Kingdom: Oxford University Press, 2008; Vol. 23, issue 3:462-77.
42. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology 2012; Vol. 28, issue 7:509-15.
43. Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Review of Clinical Pharmacology 2014; Vol. 7, issue 5:623-31.
44. Vause TD, Cheung AP, Sierra S, Claman P, Graham J, Guillemin JA, et al. Ovulation induction in polycystic ovary syndrome.. Journal of Obstetricians and Gynaecolists of Canada 2010;32(5):495-502. Erratum in Journal of Obstetricians and Gynaecolists of Canada 2010;32(11):1027 (Steward, Sabrina corrected to Stewart, Sabrina). Erratum in Journal of Obstetricians and Gynaecolists of Canada 2011;33(1):12.
45. Vitek W, Alur S, Hoeger KM. Off-label drug use in the treatment of polycystic ovary syndrome. Fertility and Sterility 2015; Vol. 103, issue 3:605-11.